#ASCO24 | Mirasol Phase 3 trial in platinum-resistant #ovariancancer confirms the efficacy of MIRV conjugated drug antibody in patients >65 y/o. Results ▶️ greater efficacy in overall survival rate and less toxicity, corroborating those obtained in overall population. pic.twitter.com/WVE3ej6Owo

Imaging and #AI: a predictive model of response to neoadjuvant #TNBC #BreastCancer treatment presented by Dr. Toulsie Ramtohul at #ASCO24 showing encouraging results to: ▶️ Personalize treatment for early-stage #TNBC ▶️ Engage future therapeutic de-escalation studies pic.twitter.com/ILeK3apAUr

🚨Live now 👉🏼Ishwaria Subbiah, MD, MS, FASCO, @IshwariaMD is sharing the latest data on a 5-year multicencer analysis of clinical trial participation & total cost for older adults with cancer @SarahCannonDocs @TheUSONetwork @ASCO #ASCO24 @OncoAlert www.scri.com/asco/ pic.twitter.com/8TVeDUkHC5

Did you see the news that lumpectomy instead of mastectomy gives a survival advantage for breast cancer? Have you had a mastectomy like me and are both terrified? I’m going to look at the study and report back later www.dailymail.co.uk/health/article-13489849/Mastectomy-not-work-just-removing-lump.html pic.twitter.com/jt0RT9fK19